Search - tctmd.com

Displaying 41 - 60 of 152

Sort: Relevancy | Date

News Conference News EuroPCR 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

Caitlin E. Cox

May 25, 2022

News Conference News SCAI 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

L.A. McKeown

May 22, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

‘Gaming’ the AUC for Revascularization? Study Suggests Not

Michael O'Riordan

March 25, 2021

News Conference News TCT 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

Todd Neale

October 22, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

L.A. McKeown

September 24, 2020

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Todd Neale

December 23, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

Advertisement

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Routine IVUS in Peripheral Interventions Supported by Small RCT

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

‘Gaming’ the AUC for Revascularization? Study Suggests Not

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

NOBLE at 5 Years: New Data Favor CABG for Left Main Disease

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Repeat Target-Lesion PCI: An Option for Public Reporting?

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content